ImmunogenX is a clinical-stage company founded in 2013, dedicated to addressing the critical needs of individuals with suspected or diagnosed celiac disease. With the support of a team comprised of world-renowned scientists and collaborators, ImmunogenX focuses on research in therapy, disease management, and food safety. One of their primary areas of development is a therapy called Latiglutenase.

This therapy acts as a digestive enzyme, specifically targeting unintended ingestion of gluten in the body, when used in combination with a gluten-free diet (GFD). This provides a potential solution for patients diligently following a GFD. ImmunogenX is also working on a method to monitor the health of intestinal villi, crucial for celiac disease patients.

The company aims to develop a means to measure the level of a specific drug metabolite, strongly dependent on villi health, to monitor and improve the recovery process. Furthermore, ImmunogenX has expanded research on gluten toxic peptide epitopes in wheat, barley, and rye, enabling more accurate and sensitive measurement of gluten content in food. Through their innovative research and dedication, ImmunogenX strives to provide effective solutions for individuals with celiac disease